Trial Profile
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms COMMAND-1; HEPCAT
- Sponsors Bristol-Myers Squibb
- 29 Sep 2012 Planned number of patients changed from 400 to 625.
- 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases, according to a Bristol-Myers Squibb media release.
- 30 Sep 2011 Interim results will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in November.